Enhanced D2 Spectacle Lenses: A Breakthrough in Pediatric Myopia Control for High-Risk Children

Can Enhanced Spectacle Lenses Redefine Myopia Control?

In the ongoing global fight against the myopia epidemic, researchers at the Hong Kong Polytechnic University (PolyU) and Hoya Vision Care are pioneering a new clinical trial to evaluate an enhanced spectacle lens technology for controlling myopia progression in high-risk children. The trial focuses specifically on a new generation of Defocus Incorporated Multiple Segments (D2) spectacle lenses, which represent an evolution of the original DIMS technology that previously demonstrated significant myopia control efficacy. With myopia projected to affect nearly half the world's population by 2050 and evidence indicating no safe threshold level of myopia exists, this research addresses an urgent public health concern that impacts not only quality of life but also increases the risk of blinding ocular pathologies in adulthood, including myopic macular degeneration.

The single-site, double-masked, active-controlled randomized trial is recruiting Chinese children aged 4-12 years with myopia of at least -0.75D and evidence of fast progression, defined as progression of 0.50D or more per year or axial growth of at least 0.27 mm per year. This population focus represents a significant advancement over previous studies, as it specifically targets early-onset and fast-progressing myopes – a cohort at particularly high risk for developing severe myopia in adulthood. The study employs a three-arm design with 1:1:1 randomization between the experimental arm (D2 spectacle lenses), control arm (single-vision spectacle lenses), and an auxiliary arm (original marketed DIMS spectacle lenses). A distinctive feature of the trial is its crossover component, where control subjects will switch to the experimental D2 lenses after the first year, allowing researchers to assess adaptation and efficacy following the transition while maintaining ethical standards by not withholding potentially beneficial treatment for extended periods.

What Advances Make the D2 Lens a Promising Innovation?

The D2 spectacle lens technology represents a significant evolution of the original DIMS design, incorporating three key enhancements: increased magnitude of myopic defocus in each lens segment, a greater number of segments, and an expanded treatment zone containing these segments. These modifications are based on evidence suggesting a dose-dependent effect of myopic defocus on myopia control efficacy observed in previous studies of multifocal contact lenses and peripheral defocus spectacle lenses. Participants are instructed to wear their assigned spectacles for at least 8 hours daily, with compliance monitored through questionnaires at each follow-up visit. The primary outcome measure is the change in cycloplegic spherical equivalent refractive error over 12 months from baseline, with secondary outcomes including axial length changes measured using a partial coherence interferometer. The investigators will also collect comprehensive data on choroidal thickness, peripheral refraction, visual acuity, accommodative function, and other ocular parameters to provide a complete picture of the lenses' effects.

Statistical analysis for this trial has been carefully designed, with sample size calculations indicating 65 participants needed per arm to detect the anticipated difference of 0.315D with 90% power, accounting for an expected 10% dropout rate. The trial incorporates an interim analysis at 6 months with appropriate alpha adjustment using Bonferroni correction. Data will be analyzed using mixed repeated measures analysis of covariance while controlling for important covariates including age and baseline myopia. The efficacy of myopia control will be quantified by comparing the difference in myopia progression between experimental and control arms relative to progression in the control arm. To ensure robust conclusions despite potential missing data, the analysis will follow an intention-to-treat approach with multiple imputation procedures. The trial also includes comprehensive safety monitoring, though previous research with the original DIMS lenses has demonstrated no significant adverse effects on visual function in children.

Will Comprehensive Insights Transform Pediatric Myopia Treatment?

This clinical trial addresses several important gaps in current myopia control research. By specifically targeting children with early-onset and fast-progressing myopia, it provides much-needed data on a high-risk population that requires urgent intervention. The modified D2 lens design, based on the scientifically established principle that ocular growth responds to optical defocus in a dose-dependent manner, represents a logical progression in the development of myopia control spectacles. The study's comprehensive measurement protocol, including assessment of choroidal thickness and peripheral refraction, may yield important insights into the mechanisms underlying myopia progression and control. The findings could significantly influence clinical practice by providing evidence-based guidance for managing high-risk pediatric myopia cases, potentially establishing D2 lenses as a preferred first-line treatment option given the favorable safety profile of spectacle-based interventions compared to contact lenses or pharmaceutical approaches.

While the trial has been meticulously designed, some limitations should be acknowledged. The one-year controlled phase, though ethically appropriate, may limit assessment of long-term efficacy. The single-ethnicity cohort (Chinese children) may affect generalizability to other populations. The reliance on self-reported compliance questionnaires introduces potential recall bias. Despite these limitations, the study represents an important advancement in myopia control research with significant clinical implications. The findings will be disseminated through scientific conferences, peer-reviewed journals, and direct communication with study participants and their families, ensuring that this valuable research impacts both scientific understanding and clinical practice. Could this enhanced myopic defocus technology represent a significant breakthrough in managing pediatric myopia progression? The answer may significantly influence how eyecare practitioners approach early intervention for children at high risk of developing severe myopia.

As myopia rates continue to rise globally, particularly in East Asian populations, the development of more effective optical interventions becomes increasingly critical. This trial's focus on the dose-response relationship between myopic defocus and myopia control efficacy addresses fundamental questions about optimizing treatment parameters. If the D2 lenses demonstrate superior efficacy compared to both single-vision lenses and the original DIMS design, this could establish important principles for future spectacle lens development and potentially influence other myopia control modalities like contact lenses and pharmaceutical treatments. How might these findings influence the approach to myopia progression in very young children, particularly those showing signs of rapid progression? Could early intervention with enhanced defocus technology fundamentally alter the trajectory of refractive development in high-risk populations? The answers to these questions have profound implications for reducing the global burden of high myopia and its associated complications.

Summary

Researchers at Hong Kong Polytechnic University and Hoya Vision Care are conducting a clinical trial to evaluate enhanced D2 spectacle lenses for controlling myopia progression in high-risk children. The study targets Chinese children aged 4-12 years with myopia of at least -0.75D and fast progression (≥0.50D per year or axial growth ≥0.27 mm per year). The D2 lens technology represents an evolution of the original DIMS design, featuring increased myopic defocus magnitude, more segments, and an expanded treatment zone. The randomized, double-masked trial employs a three-arm design comparing D2 lenses against single-vision lenses and original DIMS lenses, with a crossover component where control subjects switch to D2 lenses after one year. The primary outcome measure is change in cycloplegic spherical equivalent refractive error over 12 months, with secondary outcomes including axial length changes and comprehensive ocular parameters. With myopia projected to affect nearly half the world's population by 2050, this research addresses an urgent public health concern. The study specifically targets early-onset and fast-progressing myopes at high risk for developing severe myopia and associated blinding complications in adulthood. The trial's comprehensive measurement protocol may yield important insights into myopia progression mechanisms and establish evidence-based guidance for managing high-risk pediatric cases.